Pull to refresh
Logo
Rattlesnake blood proteins outmatch standard antivenom in lab tests

Rattlesnake blood proteins outmatch standard antivenom in lab tests

New Capabilities

Naturally evolved toxin blockers neutralized viper venom from multiple species with roughly 10 times the potency of current treatment

Today: ScienceDaily reports the finding

Overview

Updated 1 hour ago

Snakebites kill 80,000 to 140,000 people a year, and the standard treatment has barely changed in 130 years. Researchers found that proteins naturally present in rattlesnake blood neutralize venom from multiple viper species — about 10 times more potently than the leading commercial antivenom.

These proteins, called FETUAs, evolved from an ancestral blood protein called Fetuin-A to shield snakes from their own venom. The finding, published in the Proceedings of the National Academy of Sciences, points toward antivenoms that are cheaper, safer, and broader-acting than today's approach of immunizing horses and sheep with venom and harvesting their antibodies.

Why it matters

Cheaper, lab-produced antivenoms could save tens of thousands of lives in rural regions where current treatments are too costly or unavailable.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

10x
Potency vs. commercial antivenom
FETUA protein combinations were about 10 times more potent than sheep-derived rattlesnake antivenom in lab tests.
80,000–140,000
Annual snakebite deaths
Global estimate from the World Health Organization; snakebite is one of the world's most neglected tropical diseases.
4
FETUA proteins studied
Four Fetuin-A derived metalloproteinase inhibitors from western diamondback rattlesnake blood were tested in combinations.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Play

Exploring all sides of a story is often best achieved with Play.

Most of these play right now — no account needed. Sign up to save scores, keep a streak, and unlock Debate and Predict. Log in Sign Up
Predict 3 ways this could play out. Back the one you believe — contrarian picks score more when a scenario has a resolution date. Log in to play

People Involved

Organizations Involved

Timeline

January 2022 September 2026

4 events Latest: Today
Tap a bar to jump to that date
  1. ScienceDaily reports the finding

    Today Media

    ScienceDaily featured the discovery in its science news roundup, drawing renewed attention to the potential for a new class of nature-inspired antivenoms.

  2. Study published in PNAS

    Publication

    Peer-reviewed results appeared in the Proceedings of the National Academy of Sciences, showing FETUA combinations are about 10 times more potent than sheep-derived antivenom and protect against multiple viper species.

  3. Preprint posted on bioRxiv

    Publication

    The FETUA combination study was posted as a preprint, describing how four rattlesnake metalloproteinase inhibitors work together to neutralize viper venom lethality.

  4. FETUA-3 protein identified

    Discovery

    Carroll's lab found FETUA-3, a single protein in western diamondback rattlesnake blood that blocks many metalloproteinase toxins in venom.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

1894–1896

Calmette's first antivenom (1894)

French physician Albert Calmette developed the first antivenom against cobra venom at the Pasteur Institute in Saigon. He immunized horses with increasing doses of venom and collected antibodies from their blood.

Then

The horse-based approach spread worldwide and became the dominant method of antivenom production.

Now

More than 130 years later, most antivenoms are still made by immunizing large animals and harvesting antibodies.

Why this matters now

This study's recombinant protein approach departs from the century-old animal immunization model, potentially offering a cheaper and safer alternative.

1978–1982

Recombinant human insulin (1982)

Genentech scientists cloned the human insulin gene into E. coli bacteria in 1978. The first recombinant human insulin product, Humulin, won FDA approval in 1982, replacing insulin extracted from pigs and cows.

Then

Patients gained a purer, more consistent insulin supply. Production scaled without animal dependence.

Now

Recombinant production became the standard for therapeutic proteins, lowering costs and improving safety.

Why this matters now

FETUA-based antivenoms follow the same trajectory: replacing animal-derived products with lab-produced proteins that can be manufactured at scale.

Sources

(7)